Pharmacology and clinical efficacy of bisphosphonates

Current Opinion in Oncology

Volumn 10, Issue 6, 1998, Pages 566-571

  Berenson, James R ^a   Lipton, Allan ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

BONE DISEASE; BONE METASTASIS; DRUG EFFICACY; HYPERCALCEMIA; OSTEOCLAST; OSTEOLYSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; REVIEW; TUMOR;

EID: 0031725806     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199811000-00015     Document Type: Review

References (35)

1. Body JJ: Bisphosphonates. Eur J Cancer 1998, 34:263-269. An excellent review of the biology of bisphosphonates.
2. Lin JH: Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996, 18:75-85. This paper reviews the pharmacology of these drugs.
3. Stashenko P, Dewhirts FE, Peros WJ, Kent RL, Ago JM: Synergistic interactions between interleukin I, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol 1987, 138:1464-1468.
4. Mundy GR: Mechanisms of osteolytic bone destruction. Bone 1991, 12(suppl 1):1-6.
5. Belch AR, Bergsagel DE, Wilson K, O'Reilly S, Wilson J, Sutton D, et al.: Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991, 9:1397-1402.
6. Kyle RA, Jowsey J, Kelly PJ, Taves DR: Multiple myeloma bone disease: the comparative effect of sodium fluoride and calcium carbonate or placebo. N Engl J Med 1975, 293:1334-1338.
7. Man Z, Otero AB, Rendo P, Barazzutti L, Sanchez-Aralos JC: Use of pamidronate for multiple myeloma osteolytic lesions. Lancet 1990, 335:663.
8. Thiebaud D, Leyuraz S, Von Fliedner V, Perey L, Cornu P, Thiebaud S, Burckhardt P: Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 1991, 27:37-41.
9. Purohit OP, Anthony C, Radstone CR, Owen J, Coleman RE: High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994, 70:554-558.
10. Berenson J, Lichtenstein A, Porter L, Bordoni R, George S, Lipton A, et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996, 334:488-493. The efficacy of intravenous pamidronate in reducing skeletal complications of myeloma patients is demonstrated.
11. Lahtinen R, Laakso M, Palva I, et al.: Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992, 340:1049-1052.
12. Heim ME, Clemens MR, Queisser W, Pecherstorfer M, Boewer C, Herold M, et al.: Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment: a multicenter study. Onkologie 1995, 18:439-448.
13. McCloskey EV, MacLennan ICM, Drayson MT, Chapman C, Dunn J, Kanis JA: A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998, 100:317-325.
14. Brincker H, Westin J, Abildgaard N, Gimsing P, Turesson I, Hedenus M, et al.: Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Br J Haematol 1998, 101:280-286.
15. Kellihan MJ, Mangino PD: Pamidronate. Ann Pharmacother 1992, 26:1262-1269.
16. Berenson J, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998, 16:593-602. This study shows that intravenous pamidronate improves survival in myeloma patients in whom first-line chemotherapy fails.
17. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998, 12:220-229.
18. Savage AD, Belson DJ, Vescio RA, et al.: Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients [abstract]. Blood 1996, 88:105.
19. Siris ES, Hyman GA, Canfield RE: Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med 1983, 74:401-406.
20. Elomaa I, Blomqvist C, Grohn P, Porkka L, Kairento AL, Selander K, et al.: Long-term controlled trial of bisphosphonate in patients with osteolytic bone metastases. Lancet 1983, 1:146-149.
21. Paterson AHG, Powles TJ, Kanis TA, McCloskey E, Hanson J, Ashley S: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11:59-65.
22. Coleman RE, Woll PJ, Miles M, Scrivener W, Rubens RD: Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD). Br J Cancer 1988, 48:621-625.
23. Morton AR, Cantrill JA, Pillai GV, McMahon A, Anderson DC, Howell A: Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ 1988, 297:772-773.
24. Burckhardt P, Thiebaud D, Percy L, von Fliedner V: Treatment of tumor-induced osteolysis by APD. Recent Results Cancer Res 1989, 116:54-66.
25. Ette JW, Bijvoet OL, Cleton FJ, van Oosterom AT, Sleeboom HP: Osteolytic bone metastases in breast carcinoma: pathogenesis, morbidity, and bisphosphonate treatment. Eur J Cancer Clin Oncol 1986, 22:493-500.
26. Van Holten-Verzantvoort ATM, Zwinderman AH, Aaronson NK, Hermans J, van Emmerick B, van Dam FSAM: The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 1991, 27:544-549.
27. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, Cleton FJ, Beex LVAM, Blijham G: Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11:493-498.
28. Glover D, Lipton A, Keller A, Miller AA, Browning S, Fram RJ: Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer: a dose-seeking study. Cancer 1994, 74:2949-2955.
29. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996, 335:1785-1791. This article shows the efficacy of intravenous pamidronate in reducing skeletal complications of breast cancer patients who also are receiving chemotherapy.
30. Lipton A, Theriault R, Leff R, Gluck S, Stewart J, Costello S, et al.: Long term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy by monthly 90 mg pamidronate (Aredia) infusions [abstract]. Proc Am Soc Clin Oncol 1997, 16:531.
31. Horlobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al.: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998, 16:2038-2044.
32. Conte PF, Latreille J, Maurik L, Calabresi F, Santos R, Campos D, et al.: Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 1996, 14:2552-2559.
33. Kanis JA, Powles T, Paterson AHG, McCloskey EV, Ashley S: Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996, 19:663-667.
34. Van Holten-Verzantvoort ATM, Hermans J, Beex LVAM, Blijham G, Cleton FJ, van Eck-Smit BCF, et al.: Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? Eur J Cancer 1996, 32A:450-454.
35. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, et al.: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med, 1998, 339:357-363. Diel et al. suggest that clodronate may reduce the development of both bone and other sites of metastases in breast cancer patients.